Sudeep Pharma IPO: The good and the bad

Summary: Sudeep Pharma, a manufacturer of pharma and specialty nutrition ingredients, is set to go public on November 21, 2025. We analyse the company’s strengths, drawbacks and past track record to help you better understand whether its IPO is worth subscribing to.

Sudeep Pharma, a manufacturer of pharma excipients and specialty nutrition ingredients, will open its IPO (initial public offering) on November 21, 2025 and close on November 25, 2025. Of the total issue size of Rs 895 crore, Rs 95 crore comprises a fresh issue, while Rs 800 crore will be an offer for sale (OFS).

Below is a breakdown of Sudeep Pharma’s business, financials, strengths, risks and valuation to help you make an informed investment decision.

What the company does

Sudeep Pharma is a technology-driven manufacturer of excipients and specialty ingredients catering to the pharmaceutical, food and nutrition industries. The company uses in-house technologies such as encapsulation, spray drying and liposomal preparation to strengthen product innovation. The company has a meaningful presence across major global markets, including the US, Europe and Asia-Pacific.

Sudeep Pharma is among the largest producers of food-grade iron phosphate and a leading exporter of mineral ingredients from India. The company is also an early mover in liposomal ingredient technology.

Track record and valuation

When it comes to past financials, Sudeep Pharma appears to be on an impressive footing. Though the company’s revenue grew at a modest 8.2 per cent between FY23 and FY25, its PAT (profit after tax) and EBIT (earnings per share) both posted a strong growth of 49 per cent.

At the upper end of the price band (Rs 593), Sudeep Pharma’s stock is expected to be valued at 48 times its FY25 earnings and around 8.7 times its book value. There are no listed peers for comparison.

The good

Here are some of the positives of Sudeep Pharma.

#1 Market leader in the pharmaceutical and nutrition space

Sudeep Pharma is a leading manufacturer of pharmaceutical, food, nutrition and specialty ingredients, with strong positions in mineral-based products and iron phosphate. It is also one of India’s top producers of specialty food ingredients, including encapsulated preservatives widely used in the bakery segment. The company’s leadership is supported by a broad portfolio of over 100 products that span excipients and advanced ingredient solutions. A sustained focus on technology and innovation has helped it stay competitive in a high-barrier industry.

#2 Long-standing clientele

Sudeep Pharma has a wide and well-established global customer base spanning pharmaceuticals, food, nutrition and FMCG. As of June 30, 2025, it has served over 1,100 customers, including more than 40 blue-chip multinationals and 14 Fortune 500 companies. The company counts names like Pfizer, Merck, Danone, Intas and Mankind Pharma among its marquee clients.

Its largest customer contributes a modest share of revenue, indicating low concentration risk. Long-standing relationships are a key strength, with the average association with its top five customers exceeding seven years.

The bad

Below are some of the risks faced by Sudeep Pharma.

#1 Revenue concentration

Sudeep Pharma derives a large share of its revenue from the pharmaceutical, food, and nutrition segment, which consistently accounts for about two-thirds of its business. This segment spans a wide range of mineral salts, making it sensitive to regulatory changes, competitive pressures, supply-chain disruptions and shifting consumer trends. While the company has not faced material supply issues in recent years, future disruptions cannot be ruled out.

Exports are another major revenue driver, accounting for 59-68 per cent of sales across recent periods. As a result, any geopolitical, economic or trade-related developments in key global regions could materially affect its financial performance.

#2 High working capital requirements

Sudeep Pharma’s operations are working-capital intensive, with cash tied up in raw materials, inventory and receivables. Its net working capital days have more than doubled from 143 in March 2023 to 344 in June 2025, driven by higher inventory levels, more goods in transit and longer credit cycles for export customers. Large overseas buyers often demand extended payment terms, increasing the strain on working capital as the business scales. The company’s ability to secure timely and adequate working capital will be critical; any shortfall could materially impact operations, cash flows and financial performance.

#3 Competition from both domestic and foreign players

Sudeep Pharma operates in a highly competitive pharmaceutical and specialty ingredients industry marked by rapid technological change and evolving customer needs. The company faces strong domestic and global rivals, many with deeper financial resources, wider product portfolios and stronger brands. Sustaining its position will require continuous investment in R&D, process improvement, cost efficiency and customer relationships.

Competitive pressures such as aggressive pricing, superior products from peers or shifts in customer preferences could erode its market share and profitability. Any inability to respond effectively to this competition may weaken its growth prospects and adversely affect its financial performance.

Where will the IPO proceeds go?

Of the fresh issue size of Rs 95 crore, Sudeep Pharma plans to allocate nearly Rs 76 crore towards the purchase of machinery for its production line located at Nandaseri. The remaining funds will be deployed for general corporate purposes.

Should you apply for the Sudeep Pharma IPO?

Sudeep Pharma checks the right boxes – strong financials, leadership in its niche and a high-quality customer base. Yet, risks such as dependence on key segments and intense competitive pressure cannot be overlooked.

Which is why at Value Research Stock Advisor, we help you focus on companies with durable performance and transparent track records, so you don’t feel compelled to chase every IPO. Instead, you invest in businesses that compound steadily and support long-term wealth creation.

Explore Stock Advisor today

Also read: The value of failure